Discovery of the first-in-class potent and isoform-selective human carbonic anhydrase III inhibitors.


Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 25 4 2023
pubmed: 24 4 2023
entrez: 24 04 2023
Statut: ppublish

Résumé

Considering the unrecognised physio-pathological role of human carbonic anhydrase III (hCA III), a structure-based drug design was set up to identify the first-in-class potent and selective inhibitors of this neglected isoform. hCA III targeting was planned considering a unique feature of its active site among the other hCA isoforms,

Identifiants

pubmed: 37092262
doi: 10.1080/14756366.2023.2202360
pmc: PMC10128460
doi:

Substances chimiques

Carbonic Anhydrase Inhibitors 0
Sulfonamides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2202360

Références

Nature. 2005 May 5;435(7038):42
pubmed: 15875011
J Biol Chem. 1995 Jun 16;270(24):14742-7
pubmed: 7782339
J Chem Theory Comput. 2021 Jul 13;17(7):4291-4300
pubmed: 34096718
Expert Opin Ther Pat. 2018 Oct;28(10):709-712
pubmed: 30217119
Proteins. 2007 Jul 1;68(1):337-43
pubmed: 17427958
Mol Cell Biol. 2004 Nov;24(22):9942-7
pubmed: 15509796
J Med Chem. 2020 Mar 26;63(6):3317-3326
pubmed: 32031797
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1060-1068
pubmed: 32314608
Proteins. 2006 Nov 15;65(3):712-25
pubmed: 16981200
Bioorg Med Chem Lett. 2014 Sep 15;24(18):4389-4396
pubmed: 25168745
CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21
pubmed: 26215712
Head Neck. 2012 Mar;34(3):405-11
pubmed: 21472888
Future Med Chem. 2023 Jan;15(1):5-7
pubmed: 36636980
J Enzyme Inhib Med Chem. 2015 Jun;30(3):420-9
pubmed: 25068727
J Biol Chem. 1994 Sep 16;269(37):23002-6
pubmed: 8083199
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jun;115(6):789-98
pubmed: 23706919
Chem Rev. 2012 Aug 8;112(8):4421-68
pubmed: 22607219
Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9828-33
pubmed: 27531955
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Enzyme Inhib Med Chem. 2009 Feb;24(1):70-6
pubmed: 18618322
Biochemistry. 2005 Aug 2;44(30):10046-53
pubmed: 16042381
Oral Oncol. 2012 Apr;48(4):325-8
pubmed: 22405883
ChemMedChem. 2022 May 18;17(10):e202200056
pubmed: 35266325
Oral Oncol. 2013 Apr;49(4):287-92
pubmed: 23182398
Nucleic Acids Res. 2021 Jan 8;49(D1):D437-D451
pubmed: 33211854
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1545-1554
pubmed: 32746656
Bioorg Med Chem. 2007 Jul 1;15(13):4336-50
pubmed: 17475500
Bioorg Med Chem. 2007 Dec 1;15(23):7229-36
pubmed: 17826101
Future Med Chem. 2014 Jun;6(10):1149-65
pubmed: 25078135
Acta Crystallogr D Biol Crystallogr. 2010 May;66(Pt 5):616-27
pubmed: 20445237
J Neurol Sci. 1983 Jun;59(3):383-8
pubmed: 6410007
Nature. 2008 Mar 6;452(7183):56-61
pubmed: 18322527
Nat Rev Drug Discov. 2008 Feb;7(2):168-81
pubmed: 18167490
Eur J Med Chem. 2020 Mar 15;190:112112
pubmed: 32044580
Expert Opin Ther Pat. 2018 Oct;28(10):745-754
pubmed: 29973089
Cells. 2020 Mar 13;9(3):
pubmed: 32183030
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4170-4
pubmed: 8633035
Proteomics. 2007 Jun;7(12):2121-9
pubmed: 17514684
Eur J Med Chem. 2018 May 25;152:1-9
pubmed: 29684705
J Biol Chem. 1971 Apr 25;246(8):2561-73
pubmed: 4994926
ISME J. 2019 Aug;13(8):2094-2106
pubmed: 31024153
Int J Mol Sci. 2022 Nov 10;23(22):
pubmed: 36430304
J Enzyme Inhib Med Chem. 2013 Apr;28(2):231-9
pubmed: 22803676
IUBMB Life. 2004 Jun;56(6):343-7
pubmed: 15370882
Eur J Biochem. 1989 Jan 15;179(1):233-9
pubmed: 2917563
Arch Biochem Biophys. 1981 Oct 15;211(2):632-42
pubmed: 6272648
Biochim Biophys Acta. 2002 Sep 23;1599(1-2):21-7
pubmed: 12484342
Biomed Chromatogr. 2013 Sep;27(9):1157-61
pubmed: 23605884
FEBS Lett. 2000 Oct 6;482(3):237-41
pubmed: 11024467
Expert Opin Drug Discov. 2017 Jan;12(1):61-88
pubmed: 27783541
Future Med Chem. 2021 Nov;13(22):1935-1937
pubmed: 34498952
Mol Carcinog. 2008 Dec;47(12):956-63
pubmed: 18444244
J Enzyme Inhib Med Chem. 2015 Apr;30(2):325-32
pubmed: 24766661
Bioorg Med Chem. 2016 Aug 15;24(16):3612-7
pubmed: 27290692
BMC Mol Biol. 2010 Mar 31;11:25
pubmed: 20356370

Auteurs

Simone Giovannuzzi (S)

NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, Firenze, Italy.

Alessandro Bonardi (A)

NEUROFARBA Department, Laboratory of Molecular Modeling, Cheminformatics & QSAR, University of Florence, Firenze, Italy.

Paola Gratteri (P)

NEUROFARBA Department, Laboratory of Molecular Modeling, Cheminformatics & QSAR, University of Florence, Firenze, Italy.

Alessio Nocentini (A)

NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, Firenze, Italy.
NEUROFARBA Department, Laboratory of Molecular Modeling, Cheminformatics & QSAR, University of Florence, Firenze, Italy.

Claudiu T Supuran (CT)

NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, Firenze, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH